Breaking Down Shenzhen Chipscreen Biosciences Co., Ltd. Financial Health: Key Insights for Investors

Born in March 2001 from a team of senior Ph.D. returnees, Shenzhen Chipscreen Biosciences Co., Ltd. has grown into a biotech force tackling malignant tumors, metabolic and autoimmune disorders, CNS diseases and antivirals through a global development strategy that marries China-based early research with AI-assisted design and chemical genomics; the company now spans a global industrial layout-including Shenzhen and Chengdu R&D/GMP bases plus Beijing, Shanghai and a U.S. arm-and has filed over 700 invention patents (with more than 200 granted), supported two innovative drugs with multiple indications marketed globally, and continues to drive pioneering programs grounded in core values of innovation, integrity, collaboration, excellence and community commitment.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Intro

• Founding: March 2001 by senior Ph.D. returnees from the U.S.
• Strategic focus: original innovative small-molecule drugs (oncology, metabolic, autoimmune, CNS, antiviral)
• R&D model: integrated platform - AI-assisted drug design + chemical genomics + translational biology
• Global approach: early discovery in China, global clinical development, and worldwide commercialization

• Discover and develop original, affordable, and accessible innovative drugs that address unmet medical needs globally.
• Translate cutting-edge science into safe, effective therapies through rigorous R&D and responsible commercialization.

• Become a world-leading Chinese-origin biopharmaceutical company delivering multiple first-in-class or best-in-class medicines to patients worldwide.
• Build a sustainable, technology-driven drug discovery engine that shortens timelines from discovery to patient access.

• Scientific excellence - prioritize rigorous, reproducible research and continuous innovation.
• Patient-centricity - place patient needs and access at the center of decision-making.
• Global collaboration - pursue partnerships and global clinical development to maximize patient reach.
• Integrity and compliance - adhere to ethical standards, regulatory requirements, and transparent governance.
• Talent empowerment - attract, retain, and empower multidisciplinary teams with international experience.

• Scale integrated discovery platforms: expand AI and chemical-genomics capabilities to increase hit-to-lead efficiency and reduce attrition.
• Advance prioritized pipelines: progress multiple INDs and global clinical programs in oncology and systemic diseases with clear differentiation.
• Protect innovation: leverage a growing patent portfolio (>700 filings, >200 grants) to secure global freedom-to-operate and licensing options.
• Commercial execution: support marketed assets across geographies while preparing launch readiness for subsequent approvals.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Overview

Mission Statement

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) is dedicated to providing patients with affordable, clinically urgent, and revolutionary innovative drugs by developing groundbreaking therapies with new mechanisms of action, using an integrated technology platform that combines AI‑assisted design and chemical genomics, and pursuing a global development strategy rooted in early-stage research in China.

• Focus on urgent clinical needs through novel mechanisms of action and differentiated therapeutic approaches.
• Global development strategy: early-stage discovery in China, global clinical development and commercialization.
• Integrated platform: AI-assisted drug design + chemical genomics + full industry chain from discovery to commercialization.

Strategic Capabilities and Intellectual Property

• Comprehensive industry chain covering early exploratory discovery through commercialization, enabling accelerated translation of preclinical assets to market.
• Extensive IP portfolio with over 700 invention patent applications filed in China and abroad and more than 200 patents granted, underpinning freedom to operate and competitive moat.
• Two innovative drugs with multiple indications marketed globally, supported by multiple R&D projects with differentiated advantages and global competitiveness.

Vision

• To be a world‑class innovator delivering affordable, urgently needed medicines worldwide by leveraging China‑based discovery, cutting‑edge AI and genomics, and global development pathways.
• To translate high‑quality scientific breakthroughs into accessible therapeutics that address major unmet medical needs across oncology, metabolic and other disease areas.

Core Values

• Patient‑centricity: prioritize clinical urgency, affordability and real patient outcomes.
• Scientific rigor: pursue novel mechanisms and validated translational science.
• Innovation at scale: protect and expand IP while deploying AI and chemical genomics for faster discovery.
• Global mindset: early research rooted in China with development and commercialization on global timelines.
• Collaborative execution: build partnerships across academia, industry and regulatory bodies to accelerate access.

Operational Highlights

• End‑to‑end capabilities enable transition from exploratory discovery to global commercialization, increasing speed to clinic and market.
• IP depth (700+ filings, 200+ grants) supports long‑term product lifecycle management and licensing opportunities.
• Marketed products and multiple differentiated R&D programs provide revenue diversification and potential upside from additional approvals and label expansions.

Further reading: Shenzhen Chipscreen Biosciences Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Mission Statement

• Innovative drug discovery focused on differentiated mechanisms of action and multi‑indication potential.
• Industrialization and GMP production capacity to ensure reliable global supply.
• IP leadership and technology protection to sustain competitive advantage.
• Customer‑centric product development for evolving application demands.
• Global footprint to accelerate clinical development, regulatory approvals, and market access.

• Headquarters, R&D center and GMP production base: Shenzhen.
• Regional headquarters, R&D center and GMP production base: Chengdu.
• Branches: Beijing and Shanghai for regulatory, clinical and commercial operations.
• International presence: Chipscreen Biosciences (USA) Co., Ltd. to support global clinical development and partnerships.

• Patents filed (China & abroad): >700 invention patents.
• Patents granted: >200 patents.
• Pipeline strategy: multiple R&D projects with differentiated advantages and global competitiveness.
• Marketed innovative drugs: two drugs with multiple indications marketed globally.

• Scientific integrity - rigorous, evidence‑based drug discovery and development.
• Patient‑first orientation - prioritizing clinical needs and outcomes.
• Quality excellence - GMP standards across production and quality systems.
• Open collaboration - partnering globally for R&D, clinical trials and commercialization.
• Continuous innovation - sustained IP generation and technology renewal.

• Advance differentiated R&D programs toward global registrational trials.
• Scale GMP production to secure multi‑region supply for marketed indications and new launches.
• Expand IP portfolio and licensing pathways to monetize technology and collaborate with partners.
• Enhance presence in key markets via local subsidiaries and strategic alliances.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Vision Statement

• Innovation is the engine: relentless investment in discovery chemistry, translational biology, and platform technologies to expand the pipeline and accelerate IND-to-approval timelines.
• Integrity as a foundation: transparent governance, rigorous compliance with regulatory standards (NMPA, FDA/EMA interactions), and ethical conduct across R&D, manufacturing, and commercialization.
• Collaboration across disciplines: cross-functional teams and external partnerships (academia, CROs, multinational pharma) to de-risk development and broaden therapeutic reach.
• Excellence in execution: GMP quality systems, clinical rigor, and commercial readiness to maximize patient access and product value.
• Commitment to community: proactive corporate social responsibility programs, patient support initiatives, and local public-health engagement.

Global industrial layout:

• Shenzhen Headquarters / R&D Center / GMP Production Base
• Chengdu Regional Headquarters / R&D Center / GMP Production Base
• Beijing Branch
• Shanghai Branch
• Chipscreen Biosciences (USA) Co., Ltd.

Key operational and financial indicators (latest reported periods):

How the core values translate into measurable actions:

• Innovation: portfolio expansion with multiple clinical and preclinical candidates; sustained R&D-to-revenue conversion targets and patent filings across major jurisdictions.
• Integrity: published corporate governance reports, compliance audits, and transparent investor communications aligning with STAR Market disclosure standards.
• Collaboration: strategic alliances for global development and co-commercialization to shorten time-to-market and share development risk.
• Excellence: continuous GMP upgrades, quality metrics tracking (batch-release yield, deviation rates), and clinical trial success-rate optimization.
• Community commitment: patient assistance programs, local employment generation, and participation in public-health initiatives.

For a deeper dive into the company's recent financial performance and investor metrics, see: Breaking Down Shenzhen Chipscreen Biosciences Co., Ltd. Financial Health: Key Insights for Investors